Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

19 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
A comprehensive profile of recurrent glioblastoma.
Campos B, Olsen LR, Urup T, Poulsen HS. Campos B, et al. Oncogene. 2016 Nov 10;35(45):5819-5825. doi: 10.1038/onc.2016.85. Epub 2016 Apr 4. Oncogene. 2016. PMID: 27041580 Review.
The impact of bevacizumab treatment on survival and quality of life in newly diagnosed glioblastoma patients.
Poulsen HS, Urup T, Michaelsen SR, Staberg M, Villingshøj M, Lassen U. Poulsen HS, et al. Cancer Manag Res. 2014 Sep 26;6:373-87. doi: 10.2147/CMAR.S39306. eCollection 2014. Cancer Manag Res. 2014. PMID: 25298738 Free PMC article. Review.
18F-FET microPET and microMRI for anti-VEGF and anti-PlGF response assessment in an orthotopic murine model of human glioblastoma.
Nedergaard MK, Michaelsen SR, Urup T, Broholm H, El Ali H, Poulsen HS, Stockhausen MT, Kjaer A, Lassen U. Nedergaard MK, et al. PLoS One. 2015 Feb 13;10(2):e0115315. doi: 10.1371/journal.pone.0115315. eCollection 2015. PLoS One. 2015. PMID: 25680186 Free PMC article.
RESULTS: Anti-VEGF monotherapy increased survival and decreased 18F-FET uptake, BLI and MVD, while no additive effect of anti-PlGF was observed. 18F-FET SUV max tumour-to-brain (T/B) ratio was significantly lower after one week (114 ± 6%, n = 11 vs. 143 ± 8%, n = 13; p = 0 …
RESULTS: Anti-VEGF monotherapy increased survival and decreased 18F-FET uptake, BLI and MVD, while no additive effect of anti-PlGF was obser …
Development and validation of a prognostic model for recurrent glioblastoma patients treated with bevacizumab and irinotecan.
Urup T, Dahlrot RH, Grunnet K, Christensen IJ, Michaelsen SR, Toft A, Larsen VA, Broholm H, Kosteljanetz M, Hansen S, Poulsen HS, Lassen U. Urup T, et al. Acta Oncol. 2016;55(4):418-22. doi: 10.3109/0284186X.2015.1114679. Epub 2016 Feb 1. Acta Oncol. 2016. PMID: 26828563
Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients.
Urup T, Michaelsen SR, Olsen LR, Toft A, Christensen IJ, Grunnet K, Winther O, Broholm H, Kosteljanetz M, Issazadeh-Navikas S, Poulsen HS, Lassen U. Urup T, et al. Mol Oncol. 2016 Oct;10(8):1160-8. doi: 10.1016/j.molonc.2016.05.005. Epub 2016 May 26. Mol Oncol. 2016. PMID: 27262894 Free PMC article.
The prognostic value of FET PET at radiotherapy planning in newly diagnosed glioblastoma.
Poulsen SH, Urup T, Grunnet K, Christensen IJ, Larsen VA, Jensen ML, Af Rosenschöld PM, Poulsen HS, Law I. Poulsen SH, et al. Among authors: urup t. Eur J Nucl Med Mol Imaging. 2017 Mar;44(3):373-381. doi: 10.1007/s00259-016-3494-2. Epub 2016 Aug 23. Eur J Nucl Med Mol Imaging. 2017. PMID: 27554774 Free PMC article.
Transcriptional changes induced by bevacizumab combination therapy in responding and non-responding recurrent glioblastoma patients.
Urup T, Staunstrup LM, Michaelsen SR, Vitting-Seerup K, Bennedbæk M, Toft A, Olsen LR, Jønson L, Issazadeh-Navikas S, Broholm H, Hamerlik P, Poulsen HS, Lassen U. Urup T, et al. BMC Cancer. 2017 Apr 18;17(1):278. doi: 10.1186/s12885-017-3251-3. BMC Cancer. 2017. PMID: 28420326 Free PMC article.
Molecular profiling of short-term and long-term surviving patients identifies CD34 mRNA level as prognostic for glioblastoma survival.
Michaelsen SR, Urup T, Olsen LR, Broholm H, Lassen U, Poulsen HS. Michaelsen SR, et al. Among authors: urup t. J Neurooncol. 2018 May;137(3):533-542. doi: 10.1007/s11060-017-2739-7. Epub 2018 Jan 5. J Neurooncol. 2018. PMID: 29305787
Toxicity and efficacy of lomustine and bevacizumab in recurrent glioblastoma patients.
Jakobsen JN, Urup T, Grunnet K, Toft A, Johansen MD, Poulsen SH, Christensen IJ, Muhic A, Poulsen HS. Jakobsen JN, et al. Among authors: urup t. J Neurooncol. 2018 Apr;137(2):439-446. doi: 10.1007/s11060-017-2736-x. Epub 2018 Jan 12. J Neurooncol. 2018. PMID: 29330749
Biomarkers in Recurrent Grade III Glioma Patients Treated with Bevacizumab and Irinotecan.
Toft A, Urup T, Christensen IJ, Michaelsen SR, Lukram B, Grunnet K, Kosteljanetz M, Larsen VA, Lassen U, Broholm H, Poulsen HS. Toft A, et al. Among authors: urup t. Cancer Invest. 2018 Feb 7;36(2):165-174. doi: 10.1080/07357907.2018.1430818. Epub 2018 Feb 2. Cancer Invest. 2018. PMID: 29393706 Review.
19 results
Jump to page
Feedback